Using a new drug combination to fight malaria drug resistance
Official title: Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance
Funded at Weill Medical Coll of Cornell Univ · NIH-11139809 · Data updated 2026-11-12
This study is looking at a new combination of medicines to help treat malaria in young children, especially since some treatments aren't working as well anymore, and it aims to find a safer and more effective option for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $96,578 |
| NIH project number | 3R01AI177635-02S1 |
| Project ID | NIH-11139809 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old who are diagnosed with malaria and may be experiencing drug resistance.
✕Less likely to help
Patients who do not have malaria or are over the age of 11 may not receive any benefit from this research.
What this research studies
This research focuses on addressing the growing problem of drug resistance in malaria, particularly in young children. The team is investigating a novel drug combination that includes an artemisinin analogue and a proteasome inhibitor, which has shown promise in overcoming resistance to traditional malaria treatments. By targeting the Plasmodium falciparum parasite at various stages of its life cycle, the research aims to enhance the effectiveness of existing therapies and provide a new treatment option for malaria. Patients may be involved in trials to test the safety and efficacy of this new treatment approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for malaria, particularly for patients who have developed resistance to current medications.
How similar studies have gone: Other research has shown success with similar approaches in targeting drug-resistant malaria, indicating potential for this novel treatment strategy.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Lin, Gang — Weill Medical Coll of Cornell Univ
- Study coordinator: Lin, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.